Diffusion-weighted Imaging Study in Cancer of the Ovary

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

134 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-08-31

Study Completion Date

2018-10-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project seeks to develop a quantitative imaging biomarker for evaluating and monitoring treatment response in ovarian cancer metastases and assess its potential in monitoring treatment response. This will involve standardising DW-MRI for the abdomen and pelvis across multiple centres and platforms, assessing reproducibility of the measurement in patients planned for neoadjuvant chemotherapy and assessing its utility as an early response biomarker in patients with platinum-sensitive relapse due to receive therapy with carboplatin. Scanning measurements will be correlated with histopathological markers in tumour samples in order to link the biomarker with response mechanisms.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence

NCT05856409

68Ga-FAPI Ovarian Cancer Epithelial Ovarian Cancer +1 more

RECRUITING

Motion Correction in Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) in Ovarian Cancer: A Pilot Study

NCT00946140

Ovarian Cancer

COMPLETED

A Prospective Cohort Study of 68ga-FAPI-pet-ct Versus FDG-pet-ct for Ovarian Cancer

NCT05824247

Ovarian Cancer

UNKNOWN

Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)

NCT00959582

Ovarian Cancer Primary Peritoneal Cancer Fallopian Tube Cancer

COMPLETED PHASE1

Satisfactory Debulking Prediction Model for Advanced Ovarian Cancer Based on PET-CT Image Data

NCT06533709

Ovarian Cancer Image Predation

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ovarian Cancer Peritoneal Metastases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Biological validation cohort 1

No interventions assigned to this group

Response assessment cohort 2

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed ovarian, primary peritoneal or fallopian tube cancer stage III or IV
* Scheduled to receive neoadjuvant chemotherapy (carboplatin/cisplatin)with planned debulking surgery.